Patents by Inventor Hakan BLADH

Hakan BLADH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 8338587
    Abstract: The present invention provides named compounds of formula (I) and pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: December 25, 2012
    Assignee: AstraZeneca AB
    Inventors: Frank Burkamp, Peter Hansen, Balint Gabos, Håkan Bladh
  • NOVEL COMPOUNDS
    Publication number: 20120178726
    Abstract: The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: March 12, 2012
    Publication date: July 12, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Håkan Bladh, Frank Burkamp, Balint Gabos, Peter Hansen, Svetlana Ivanova, Karolina Lawitz
  • Glucocorticosteroids, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
    Patent number: 8163724
    Abstract: The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: April 24, 2012
    Assignee: AstraZeneca AB
    Inventors: Håkan Bladh, Frank Burkamp, Balint Gabos, Peter Hansen, Svetlana Ivanova, Karolina Lawitz
  • 16 Alpha, 17 Alpha-Acetal Glucocorticosteroidal Derivatives and their Use
    Publication number: 20110294766
    Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 27, 2009
    Publication date: December 1, 2011
    Applicant: AstraZeneca AB
    Inventors: Frank Burkamp, Tesfaledet Mussie, Paul Andersson, Inga-Britt Andersson, Sumita Bhatacharyya, Håkan Bladh, Svetlana Ivanova, Matti Lepistö
  • Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists
    Publication number: 20110160167
    Abstract: The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 18, 2008
    Publication date: June 30, 2011
    Applicant: AstraZeneca AB
    Inventors: Håkan Bladh, Karl Edman, Thomas Hansson, Karolina Lawitz, Matti Lepistö, Tesfaledet Mussie
  • Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases
    Publication number: 20110130426
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).
    Type: Application
    Filed: October 26, 2005
    Publication date: June 2, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Håkan Bladh, Krister Henriksson, Vijaykumar Hulikal, Matti Lepistö
  • NOVEL COMPOUNDS
    Publication number: 20100256103
    Abstract: The present invention provides named compounds of formula (I) and pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: March 30, 2010
    Publication date: October 7, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Frank Burkamp, Peter Hansen, Balint Gabos, Håkan Bladh
  • NOVEL COMPOUNDS
    Publication number: 20090286835
    Abstract: The present invention provides compounds of formula (I) wherein n, p, R1, R2, X1, X2, X3, X4, X5, R3a, R3b, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: October 3, 2008
    Publication date: November 19, 2009
    Applicant: AstraZeneca AB
    Inventors: Hakan BLADH, Frank Burkamp, Balint Gabos, Peter Hansen, Svetlana Ivanova, Karolina Lawitz
  • Sulphonamide Derivatives as Modulators of the Glucocorticoid Receptor
    Publication number: 20090170898
    Abstract: Compounds of formula (I): or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).
    Type: Application
    Filed: March 29, 2007
    Publication date: July 2, 2009
    Inventors: Malena Bengtsson, Håkan Bladh, Thomas Hansson, Elizabeth Kinchin
  • Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases
    Publication number: 20090124607
    Abstract: Compounds of formula (I): or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).
    Type: Application
    Filed: October 18, 2006
    Publication date: May 14, 2009
    Inventors: Hakan Bladh, Jan Dahmen, Thomas Hansson, Krister Henriksson, Matti Lepisto, Stinabritt Nilsson
  • Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases
    Publication number: 20090093485
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).
    Type: Application
    Filed: October 26, 2005
    Publication date: April 9, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Hakan Bladh, Krister Henriksson, Vijaykumar Hulikal, Matti Lepisto
  • Use of Unsaturated Quionoline or Naphtalene Derivatives as Medicaments
    Publication number: 20090036484
    Abstract: A compound of formula (I): (I), or a pharmaceutically acceptable salt thereof; for use as a medicament (for example modulating the glucocorticoid receptor in a warm blooded animal), and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: October 26, 2005
    Publication date: February 5, 2009
    Applicant: AstraZeneca AB
    Inventor: Hakan Bladh
  • Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases
    Publication number: 20070249648
    Abstract: The invention provides compounds of general formula. wherein A, B, W, X, Y, Z, D, E, R1 and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: October 21, 2004
    Publication date: October 25, 2007
    Inventors: Håkan Bladh, Stephen Connolly, Hazel Dyke, Annea Lisius, Stephen Price, Igor Shamovsky, Marco Van Den Heuvel
  • Quinoline derivatives as neutrophil elastase inhibitors and their use
    Publication number: 20070010551
    Abstract: There are provided novel compounds of formula (I) wherein R1, R3, R4, R5, G1, G2, L and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Application
    Filed: August 25, 2004
    Publication date: January 11, 2007
    Inventors: Hakan Bladh, Joakim Larsson
  • Quinoxaline derivatives as neutrophil elastase inhibitors and their use
    Publication number: 20060270666
    Abstract: There are provided novel compounds of formula (I) wherein R1, R4, R5, G1, G2, L and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Application
    Filed: August 25, 2004
    Publication date: November 30, 2006
    Inventors: Hakan Bladh, Joakim Larsson
  • Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof
    Patent number: 7030246
    Abstract: Compounds of formula (I) are modulators of STAT6 signal pathway activity, and can be used in the treatment of atopic dermatitis, urticaria, allergic asthma, allergic rhinitis, a food allergy, allergic conjunctivitis, hayfever, bullous pemphigoid, industrial sensitization, chronic rejection of transplants or COPD
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: April 18, 2006
    Assignee: Astrazeneca AB
    Inventors: Håkan Bladh, Thomas Hansson, Grigorios Nikitidis, Carita Nordén, Lars Pettersson, Mikael Varga
  • 2-Pyridone derivatives as inhibitors of neutrophile elastase
    Publication number: 20060035938
    Abstract: There are provided novel compounds of formula (I) wherein R1?, R4?. R5?, G1?, G2?, X, L, Y1?, Y2? and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors or neutrophil elastase.
    Type: Application
    Filed: November 11, 2003
    Publication date: February 16, 2006
    Inventors: Hakan Bladh, Tomas Klingstedt, Joakim Larsson, Karolina Lawitz, Matti Lepisto, Hans Lonn, Grigorios Nikitidis
  • Tetrahydroquinoline derivatives as stat6-modulators, preparation and use thereof
    Publication number: 20040132724
    Abstract: Compounds of formula (I) are modulators of STAT6 signal pathway activity, and can be used in the treatment of atopic dermatitis, urticaria, allergic asthma, allergic rhinitis, a food allergy, allergic conjunctivitis, hayfever, bullous pemphigoid, industrial sensitization, chronic rejection of transplants or COPD.
    Type: Application
    Filed: September 29, 2003
    Publication date: July 8, 2004
    Inventors: Hakan Bladh, Thomas Hansson, Grigorios Nikitidis, Carita Norden, Lars Pettersson, Mikael Varga